Editor's comment

**Title:** Design of the Anti-tuberculosis Drugs induced Adverse Reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS)

**Authors:**

Yin Yin Xia (yinyin_xia@yahoo.cn)
Dai Yu Hu (hukaixiou@263.net)
Fei Ying Liu (liufeiv@163.com)
Xiao Meng Wang (xmwang@cdc.zj.cn)
Yan Li Yuan (yuanyanli7500@163.com)
De Hua Tu (bata0405@126.com)
Yi Xin Chen (yix_chen@263.net)
Lin Zhou (zhoulin@chinatb.org)
Li Zhen Zhu (zhulizhen@hotmail.com)
Wei Wei Gao (gwwiys@sina.com)
Hong Yuan Wang (why99@vip.sina.com)
Da Fang Chen (dafangchen@bjmu.edu.cn)
Li Yang (lyang@bjmu.edu.cn)
Ping Ping He (pingpinghe@vip.163.com)
Xiao Ting Li (imissfriend@163.com)
Ying Jian He (mimi487@163.com)
Feng Sun (sunfeng801003@sina.com)
Si Yan Zhan (siyan-zhan@bjmu.edu.cn)

**Version:** 3  **Date:** 7 May 2010

**Editor's comment:**

This study protocol was not peer reviewed by the journal because it had already received "ethical" and funding approval by the time it was submitted. These processes of approval usually involve peer review. Also, once approved, the authors/investigators are unlikely to be able to make revisions to their protocol. On balance, then, the editors of this journal have accepted the protocol because the authors were able to supply evidence of both types of approval.

Note that study protocols that have yet to receive "ethical" and/or funding approval are peer reviewed in the normal way.

More information about our policies on study protocols is available at: http://www.biomedcentral.com/bmcpublichealth/ifora/?txt_jou_id=2024&txt_mst_id=2011

We strongly advise readers to contact the authors or compare with any published results article(s) to ensure that no deviations from the protocol occurred during the study.